Intellia Therapeutics (NTLA) EBITDA (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of EBITDA data on file, last reported at -$97.5 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$97.5 million, up 14.38% year-over-year; the trailing twelve-month figure through Mar 2026 was -$395.9 million (up 24.43% YoY), and the FY2025 annual result was -$412.3 million, up 20.46% from the prior year.
• EBITDA retreated to -$97.5 million in Q1 2026 per NTLA's latest filing, from -$95.7 million in the prior quarter.
• Over five years, EBITDA peaked at -$95.7 million in Q4 2025 and troughed at -$152.3 million in Q1 2022.
• A 5-year average of -$116.7 million and a median of -$113.0 million in 2022 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2023: EBITDA sank 229.53% in 2022, then jumped 35.43% in 2023.
• A 5-year view of EBITDA shows it stood at -$111.5 million in 2022, then dropped by 17.35% to -$130.8 million in 2023, then slipped by 0.57% to -$131.6 million in 2024, then rose by 27.24% to -$95.7 million in 2025, then retreated by 1.84% to -$97.5 million in 2026.
• Business Quant data shows NTLA's EBITDA at -$97.5 million in Q1 2026, -$95.7 million in Q4 2025, and -$101.0 million in Q3 2025.